Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02399137
Title A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merrimack Pharmaceuticals
Indications

pancreatic adenocarcinoma

Therapies

Nab-paclitaxel

Gemcitabine

MM-141

Age Groups: adult
Covered Countries USA | ESP | DEU | CAN


No variant requirements are available.